This project is motivated by neuroscientific theory regarding the role of the mesolimbic dopamine system in selective attention. It aims to elucidate how the dopamine system affects attention and to determine the role abnormal functioning of this…
ID
Source
Brief title
Condition
- Movement disorders (incl parkinsonism)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Outcome parameters are: behavioural measures of response latency and accuracy
and non-invasive electrophysiological measures in the form of event-related
potentials.
Secondary outcome
none
Background summary
The mesolimbic dopamine system has a broad impact on brain function and plays a
role in various aspects of emotional and cognitive processing. Parkinson*s
Disease (PD) causes abnormalities in this system that lead to emotional,
behavioural and cognitive symptoms, including changes in the attentional
processing of sensory input.
Study objective
This project is motivated by neuroscientific theory regarding the role of the
mesolimbic dopamine system in selective attention. It aims to elucidate how the
dopamine system affects attention and to determine the role abnormal
functioning of this system plays in creating cognitive and emotional symptoms
of PD. The study will accordingly increase our understanding of non-motor
deficits in PD and the role of dopamine replacement therapy therein.
Our hypothesis is that dopamine deficit caused by PD will have a strong
negative impact on attention and the assignment of priority to sensory stimuli.
In particular, sensitivity of attention to the novelty of stimuli and to their
reward value will be reduced. These symptoms will be alleviated when dopamine
availability is increased through dopamine replacement medication.
Study design
Cross-sectional pre-post intervention design using behavioural measures of
response time and accuracy and electroencephalographic measures of brain
activity (EEG) during execution of cognitive tasks.
Intervention
Levodopa administration after overnight withdrawal.
Study burden and risks
Participants visit the Transitorium building of the VU on one occasion and are
tested within their home on two separate days.
Day 1: Completion of a battery of pen-and-paper neuropsychological assessment
inventories; explanation of and acquaintance with EEG apparatus. VU
Transitorium building, 2 hours.
Day 2: First test session at the home of the participant. One half hour setting
up EEG recording; 1.5 hours experimental tasks. For one half of patients, tests
are done under conditions of overnight withdrawal from levodopa. For the other
half, overnight withdrawal occurs on day 3.
Day 3: Second test session; as per day 2.
None of the treatments and measurements causes any significant risk to health
or well-being of the patients or controls.
Vd Boechorststraat 1
1081 BT Amsterdam
NL
Vd Boechorststraat 1
1081 BT Amsterdam
NL
Listed location countries
Age
Inclusion criteria
Diagnosis of idiopathic PD following UK Brain Bank criteria in Hoehn and Yahr stages2-3
40-75 years old
informed consent
On DA replacement therapy
Exclusion criteria
psychotropic medication other than DA therapy (at least 4 weeks off medication)
major somatic disorder or known psychiatric diagnosis
Dementia (MMSE <23)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL32718.029.10 |